Kancera AB - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kancera AB - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Kancera AB - Product Pipeline Review - 2016', provides an overview of the Kancera AB's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Kancera AB, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kancera AB
- The report provides overview of Kancera AB including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Kancera AB's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Kancera AB's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Kancera AB's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kancera AB
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kancera AB's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Kancera AB Snapshot 5
Kancera AB Overview 5
Key Information 5
Key Facts 5
Kancera AB - Research and Development Overview 6
Key Therapeutic Areas 6
Kancera AB - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Kancera AB - Pipeline Products Glance 13
Kancera AB - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Kancera AB - Drug Profiles 15
KAN-0437757 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
KAN-0438757 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
KAN-0439834 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibodies to Target ROR-1 for Chronic Lymphocytic Leukemia and Melanoma 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
KAN-0439221 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
KAN-043936 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
KAN-0439363 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
KAN-0439365 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
KAN-0439828 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
KAN-0439829 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
KAN-439782 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Malaria 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Schistosomiasis 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit HDAC6 for Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Kancera AB - Pipeline Analysis 31
Kancera AB - Pipeline Products by Target 31
Kancera AB - Pipeline Products by Route of Administration 32
Kancera AB - Pipeline Products by Molecule Type 33
Kancera AB - Pipeline Products by Mechanism of Action 34
Kancera AB - Recent Pipeline Updates 35
Kancera AB - Dormant Projects 36
Kancera AB - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
Small Molecules To Agonize GPR-119 For Type 2 Diabetes 37
Small Molecules To Inhibit SCD1 For Obesity And Diabetes 37
Kancera AB - Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables

Kancera AB, Key Information 5
Kancera AB, Key Facts 5
Kancera AB - Pipeline by Indication, 2016 7
Kancera AB - Pipeline by Stage of Development, 2016 9
Kancera AB - Monotherapy Products in Pipeline, 2016 10
Kancera AB - Partnered Products in Pipeline, 2016 11
Kancera AB - Partnered Products/ Combination Treatment Modalities, 2016 12
Kancera AB - Preclinical, 2016 13
Kancera AB - Discovery, 2016 14
Kancera AB - Pipeline by Target, 2016 31
Kancera AB - Pipeline by Route of Administration, 2016 32
Kancera AB - Pipeline by Molecule Type, 2016 33
Kancera AB - Pipeline Products by Mechanism of Action, 2016 34
Kancera AB - Recent Pipeline Updates, 2016 35
Kancera AB - Dormant Developmental Projects,2016 36
Kancera AB - Discontinued Pipeline Products, 2016 37